What's driving this
9.9% — well past the >8% cardioprotective target, up from a 3.7% baseline. The Accentrate LPC-form fish oil overcame the FADS1/FADS2 conversion defect.
Full protocol →| Draw | Value | Status |
|---|---|---|
| June 25, 2026 | 9.9 % wt | OPTIMAL |
9.9% — well past the >8% cardioprotective target, up from a 3.7% baseline. The Accentrate LPC-form fish oil overcame the FADS1/FADS2 conversion defect.
Full protocol →| Draw | Value | Status |
|---|---|---|
| June 25, 2026 | 9.9 % wt | OPTIMAL |